ResearchPod Summary
Triple-negative breast cancer (TNBC) is a highly aggressive disease with significant inter-patient heterogeneity, leading to variable responses to standard neoadjuvant chemotherapy (NAC). While previous studies have attempted to classify TNBC using bulk tissue gene expression, these methods often conflate cancer-cell intrinsic programs with the surrounding tumor microenvironment (TME). This study utilized single-cell transcriptomic analysis of 427,857 cells from 101 treatment-naive patients and spatial transcriptomic profiling of 44 patients to resolve this complexity.
The researchers identified four patient-level cancer archetypes (ARC1–ARC4) based on pure cancer-cell gene expression, effectively separating tumor-intrinsic biology from the TME. These archetypes—Luminal Secretory-like, Basal-like, Interferon-responsive, and Androgen Receptor-enriched—show distinct clinical associations. For instance, the Interferon-responsive archetype (ARC3) is strongly associated with pathological complete response (pCR) to chemotherapy, while the Basal-like archetype (ARC2) is linked to residual disease (RD) and poorer survival outcomes. Additionally, the study identified 13 recurrent cancer-cell metaprograms, such as S-phase cell cycle activity and interferon signaling, which further correlate with treatment response.
The TME in TNBC was found to be extensively reprogrammed compared to normal breast tissue. By analyzing the co-occurrence of cancer-cell metaprograms and TME cell states, the authors defined eight cellular communities, or 'ecotypes.' These ecotypes represent coordinated biological interactions between cancer cells, immune cells, and stromal cells. Notably, the study highlights the critical role of macrophage subtypes—rather than just T cells—in modulating chemotherapy response. Macrophage states enriched in interferon and complement signaling were associated with pCR, whereas angiogenesis- and ECM-remodeling-related macrophages were enriched in RD.
To facilitate clinical translation, the researchers developed a 13-gene expression panel derived from their single-cell findings. This panel successfully predicts the risk of residual disease in independent patient cohorts and correlates with overall survival. These findings provide a high-resolution roadmap of TNBC biology, offering potential new biomarkers and therapeutic targets, such as specific macrophage populations, to improve patient outcomes.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.